FY2029 Earnings Estimate for Evolus Issued By HC Wainwright

Evolus, Inc. (NASDAQ:EOLS) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for Evolus in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of $4.43 for the year. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.63) per share.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Tuesday.

Evolus Stock Down 0.8 %

Shares of NASDAQ:EOLS opened at $14.02 on Thursday. The firm’s 50 day moving average price is $11.75 and its 200 day moving average price is $13.75. The stock has a market cap of $887.75 million, a price-to-earnings ratio of -15.41 and a beta of 1.32. Evolus has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Institutional Trading of Evolus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV acquired a new stake in Evolus during the fourth quarter worth approximately $49,000. Quarry LP acquired a new stake in Evolus during the second quarter worth approximately $54,000. Point72 Asset Management L.P. acquired a new stake in Evolus during the third quarter worth approximately $132,000. Dynamic Technology Lab Private Ltd acquired a new stake in Evolus during the third quarter worth approximately $191,000. Finally, Profund Advisors LLC acquired a new stake in Evolus during the second quarter worth approximately $130,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.